Patent 7781448 was granted and assigned to Supernus Pharmaceuticals, Inc. on August, 2010 by the United States Patent and Trademark Office.
A pharmaceutical composition of a pharmaceutically acceptable trospium salt, with upon administration to a human patient generates an average steady state blood levels of trospium with a minimum (Cmin) and maximum (Cmax) blood levels of about 0.5-2.5 ng/ml and about 2.0-6.0 ng/ml, respectively.